Opdivo gained rapid approval in the US after having gained 'Breakthrough Therapy Designation', and was also identified as a promising innovative medicine (PIM) for lung cancer by the UK's drug ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates ...

J&J has already benefitted from Halozyme’s ENHANZE tech with DARZALEX, and it looks as if OPDIVO might be another blockbuster drug that could benefit from ENHANZE tech. Essentially, Halozyme offers ...

Risk of disease recurrence or death was reduced by 42% with Opdivo compared to chemotherapy. 18-month event-free survival was 70% for Opdivo-treated patients, versus 50% for chemotherapy.

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient death in a ...

BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo ...

Opdivo® (nivolumab) is now funded in New Zealand for eligible patients with metastatic clear cell renal cell carcinoma (RCC) (advanced kidney cancer) after prior anti-angiogenic therapy.

Bristol Myers Squibb exceeded third-quarter profit expectations with $3.7 billion earnings, due to strong sales in established and new drugs. Revenue climbed 8%, hitting $11.89 billion. However, the ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...